eISSN: 1896-9151
ISSN: 1734-1922
Archives of Medical Science
Current issue Archive Manuscripts accepted About the journal Special issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
2/2018
vol. 14
 
Share:
Share:
more
 
 
abstract:
Experimental research

The role of vitamin E in the prevention of zoledronic acid-induced nephrotoxicity in rats: a light and electron microscopy study

İbrahim Unal Sert, Ozcan Kilic, Murat Akand, Lutfi Saglik, Mustafa Cihat Avunduk, Esra Erdemli

Arch Med Sci 2018; 14, 2: 381–387
Online publish date: 2016/05/30
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction: Bisphosphonates are widely used in metastatic cancer such as prostate and breast cancer, and their nephrotoxic effects have been established previously. In this study we aimed to evaluate both the nephrotoxic effects of zoledronic acid (ZA) and the protective effects of vitamin E (Vit-E) on this process under light and electron microscopy.

Material and methods: A total of 30 male Sprague-Dawley rats were divided into 3 groups. The first group constituted the control group. The second group was given i.v. ZA of 3 mg/kg once every 3 weeks for 12 weeks from the tail vein. The third group received the same dosage of ZA with an additional i.m. injection of 15 mg Vit-E every week for 12 weeks. Tissues were taken 4 days after the last dose of ZA for histopathological and ultrastructural evaluation. Paller score, tubular epithelial thickness and basal membrane thickness were calculated for each group.

Results: For group 2, the p-values are all < 0.001 for Paller score, epitelial thickness, and basal membrane thickness. For group 3 (ZA + Vit. E), the p-values are < 0.001 for Paller score, 0.996 for epitelial thickness, and < 0.001 basal membrane thickness. Significant differences were also observed in ultrastructural changes for group 2. However, adding Vit-E to ZA administration reversed all the histopathological changes to some degree, with statistical significance.

Conclusions: Administration of ZA had nephrotoxic effects on rat kidney observed under both light and electron microscopy. Concomitant administration of Vit-E significantly reduces toxic histopathological effects of ZA.
keywords:

zoledronic acid, vitamin E, nephrotoxicity, renal function, rat

references:
Patrick DL, Cleeland CS, von Moos R, et al. Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support Care Cancer 2015; 23: 1157-68.
Bergner R, Diel IJ, Henrich D, Hoffman M, Uppenkamp M. Differences in nephrotoxicity of intravenous bisphosphonates for the treatment of malignancy-related bone disease. Onkologie 2006; 29: 534-40.
Smith MR, Halabi S, Ryan CJ, et al. Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance). J Clin Oncol 2014; 10: 1143-50.
Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-32.
Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zoledronic acid prevents cancer treatment-induced bone loss n premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol 2007; 25: 820-8.
Green JR, Seltenmeyer Y, Jaeggi KA, Widler L. Renal tolerability profile of novel, potent bisphosphonates in two short-term rat models. Pharmacol Toxicol 1997; 80: 225-30.
Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-200.
Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002; 346: 653-61.
Herrera E, Barbas C. Vitamin E: action, metabolism and perspectives. J Physiol Biochem 2001; 57: 43-56.
Haleem NYA, El-Aasar HM, Zaki SM, Sabry SM, El-Zainy AW. Concomitant protective and therapeutic role of verapamil in chronic mercury induced nephrotoxicity in the adult rat: histological, morphometric and ultrastructural study. Arch Med Sci 2015; 11: 199-209.
Jun M, Venkataraman V, Razavian M, et al. Antioxidants for chronic kidney disease. Cochrane Database Syst Rev 2012; 10: CD008176.
Pfister T, Atzpodien E, Bauss F. The renal effects of minimally nephrotoxic doses of ibandronate and zoledronate following single and intermittent intravenous administration in rats. Toxicology 2003; 191: 159-67.
Paller MS, Hoidal JR, Ferris TF. Oxygen free radicals in ischemic acute renal failure in the rat. J Clin Invest 1984; 74: 1156-64.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65: 5-29.
Sweeney CJ, Chen YH, Carducci M, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med 2015; 373: 737-46.
James ND, Sydes MR, Mason MD, et al. Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomized controlled trial. Lancet Oncol 2012; 13: 549-58.
Huszno J, Badora A, Nowara E. The influence of steroid receptor status on the cardiotoxicity risk in HER2-positive breast cancer patients receiving trastuzumab. Arch Med Sci 2015; 11: 371-7.
Xu XL, Gou WL, Wang AY, et al. Basic research and clinical applications of bisphosphonates in bone disease: what have we learned over the last 40 years? J Transl Med 2013; 11: 303.
Fleisch H. Bisphosphonates in bone disease: from the laboratory to the patient, 4th ed. Parthenon Publishing Group Ltd, New York 2000; 1-212.
McKay RR, Taplin ME, Choueiri TK. Optimizing bone health and minimizing skeletal morbidity in men with prostate cancer. Hematol Oncol Clin North Am 2013; 27: 1261-83.
Cal JC, Daley-Yates PT. Disposition and nephrotoxicity of 3-amino-1-hytdroxypropylidene-1, bisphosphonate (APD), in rats and mice. Toxicology 1990; 65: 179-97.
Okazaki A, Sakai H, Matsuzawa T, Perkin CJ, East PW. Intravenous single and repeated dose toxicity studies of cimadronate (YM175), a novel bisphosphonate, in rats. J Toxicol Sci 1995; 20 Suppl 1: 15-26.
Markowitz GS, Fine PL, Stack JI, et al. Toxic acute tubular necrosis following treatment with zoledronate (Zometa). Kidney Int 2003; 64: 281-9.
Alden CL, Parker RD, Eastman DF. Development of an acute model for the study of chloromethanediphosphonate nephrotoxicity. Toxicol Pathol 1989; 17: 27-32.
Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcemia of malignancy. Drug Saf 1999; 21: 389-406.
Pfister T, Atzpodien E, Bohrmann B, Bauss F. Acute renal effects of three intravenous bisphosphonates in the rat. Basic Clin Pharmacol Toxicol 2005; 97: 374-81.
Banerjee D, Asif A, Striker L, Preston RA, Bourgoignie JJ, Roth D. Short-term, high-dose pamidronate-induced acute tubular necrosis: the postulated mechanism of bisphosphonate nephrotoxicity. Am J Kidney Dis 2003; 41: E18.
Kim JW, Tatad JCI, Landayan MEA, Kim SJ, Kim MR. Animal model for medication-released osteonecrosis of the jaw with precedent metabolic bone disease. Bone 2015; 81: 442-8.
Lühe A, Künkele KP, Haiker M, et al. Preclinical evidence for nitrogen-containing bisphosphonate inhibition of farnesyl diphosphate (FPP) synthase in the kidney: implications for renal safety. Toxicology in Vitro 2008; 22: 899-909.
Dillioglugil MO, Maral Kir H, Gulkac MD, et al. Protective effects of increasing vitamin E and a doses on cisplatin-induced oxidative damage to kidney tissue in rats. Urol Int 2005; 75: 340-4.
Patel Manali B, Deshpande S, Shah G. Evaluation of efficacy of vitamin E and N-acetyl cysteine in gentamicin-induced nephrotoxicity in rats. Ren Fail 2011; 33: 341-7.
Abdel-Hamid GA. Effect of vitamin E and selenium against aluminum-induced nephrotoxicity in pregnant rats. Folia Histochem Cytobiol 2013; 51: 312-9.
Ghlissi Z, Hakim A, Sila A, et al. Evaluation of efficacy of natural astaxanthin and vitamin E in prevention of colistin-induced nephrotoxicity in the rat model. Environ Toxicol Pharmacol 2014; 37: 960-6.
Aslanturk A, Uzunhisarcikli M, Kalender S, Demir F. Sodium selenite and vitamin E in preventing mercuric chloride induced renal toxicity in rats. Food Chem Toxicol 2014; 70: 185-90.
FEATURED PRODUCTS
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe